Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codeine + diclofenac is a combination analgesic drug consisting of codeine, an opioid analgesic, and diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). This combination is used for the management of moderate to severe pain where both inflammatory and nociceptive components are present. Codeine acts primarily as a prodrug that is metabolized to morphine in the body, exerting its effect by agonizing mu-opioid receptors in the central nervous system to reduce pain perception and induce sedation[5][8]. Diclofenac inhibits cyclooxygenase (COX)-1 and COX-2 enzymes, leading to decreased synthesis of prostaglandins involved in inflammation and pain signaling[3]. The combination may provide superior analgesia compared with either agent alone but can increase the risk of side effects such as gastrointestinal irritation (from diclofenac) or respiratory depression (from codeine)[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + diclofenac.